## FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APP	ROVAL
OMB Number	3235

0.5

3235-0287 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden hours per response:

L.

Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
	or Section 20(b) of the Investment Company Act of 1040

			or Section 30(h) of the Investment Company Act of 1940	
1. Name and Address of Reporting Person <sup>*</sup> Leonard Keith R			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Unity Biotechnology, Inc.</u> [ UBX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner v Officer (give title Other (specify
(Last) (First) (Middle) C/O UNITY BIOTECHNOLOGY, INC. 3280 BAYSHORE BOULEVARD		OGY, INC.	3. Date of Earliest Transaction (Month/Day/Year) 09/19/2019	X Onicer (give nue Oner (specify below) below) Chief Executive Officer
(Street) BRISBANE (City)	CA (State)	94005 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	(Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8)4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock, \$0.0001 par value								210,782 <sup>(1)</sup>	D	
Common Stock, \$0.0001 par value								383,475	Ι	See Footnote <sup>(2)</sup>
Common Stock, \$0.0001 par value								148,448	Ι	See Footnote <sup>(3)</sup>
Common Stock, \$0.0001 par value								152,542	Ι	See Footnote <sup>(4)</sup>

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$3.43	09/19/2019		A		35,525 <sup>(5)</sup>		09/19/2019	01/28/2028	Common Stock	35,525	\$0.00	35,525	D	

Explanation of Responses:

1. Includes Restricted Stock Units which vest over time measured from the grant date.

2. The shares are directly held by Andalucia Ventures LLC, a limited liability company in which the Reporting Person holds a controlling interest.

3. The shares are directly held by Pathfinder Investment Fund, LLC, a limited liability company in which the Reporting Person holds a controlling interest.

4. The shares are directly held by Keith Richard Leonard, Jr. 2017 Retained Annuity Trust.

5. On January 29, 2018, Reporting Person was granted an option exercisable for 142,102 shares. Twenty-five percent (25%) of the shares was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease. On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved.

## **Remarks:**

/s/ Tamara L. Tompkins

Leonard

Attorney-in-Fact for Keith R.

09/23/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.